1. Home
  2. NRIX vs STAA Comparison

NRIX vs STAA Comparison

Compare NRIX & STAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$19.12

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo STAAR Surgical Company

STAA

STAAR Surgical Company

HOLD

Current Price

$23.15

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRIX
STAA
Founded
2009
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Ophthalmic Goods
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.2B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
NRIX
STAA
Price
$19.12
$23.15
Analyst Decision
Strong Buy
Hold
Analyst Count
13
10
Target Price
$27.46
$24.56
AVG Volume (30 Days)
1.8M
1.5M
Earning Date
01-27-2026
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$83,687,000.00
$230,591,000.00
Revenue This Year
$59.40
N/A
Revenue Next Year
N/A
$21.97
P/E Ratio
N/A
N/A
Revenue Growth
48.32
N/A
52 Week Low
$8.18
$13.50
52 Week High
$22.50
$30.81

Technical Indicators

Market Signals
Indicator
NRIX
STAA
Relative Strength Index (RSI) 60.28 41.02
Support Level $18.78 $22.90
Resistance Level $19.54 $23.74
Average True Range (ATR) 0.84 1.13
MACD -0.21 -0.11
Stochastic Oscillator 68.92 6.71

Price Performance

Historical Comparison
NRIX
STAA

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About STAA STAAR Surgical Company

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.

Share on Social Networks: